Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L36 pseudogene 9 (RPL36P9) is a processed pseudogene in the human genome corresponding to the RPL36 gene[2][3][7]. Pseudogenes like RPL36P9 arise through gene duplication or retrotransposition events and usually lack the ability to encode a functional protein due to disabling mutations, loss of regulatory sequences, or truncation[4][10]. RPL36P9 is a non-coding DNA sequence related to the functional ribosomal protein L36, which is involved in forming the 60S subunit of the ribosome, essential for cellular protein synthesis[11]. However, as a pseudogene, RPL36P9 does not contribute to ribosome function or participate in biological processes and is not considered a target for drugs, disease biomarkers, or therapeutic safety concerns[3][7][13]. There are several similar pseudogenes related to ribosomal protein L36, but RPL36P9 is specifically classified as a pseudogene by expert gene nomenclature resources and has no established function or disease relevance[3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L36 pseudogene 9 (RPL36P9).